Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 23;11:591269. doi: 10.3389/fimmu.2020.591269

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Fu, Wang, Shen, Guo, Liu, Ye, Sun, Li, Tian and Wei

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Patients through the trial. One hundred patients that had been positive for HBeAg and hepatitis B surface antigen (HBsAg) for longer than 6 months and had elevated serum alanine transaminase (ALT) (>2 × ULN and <10 × ULN) and detectable baseline serum HBV DNA (>2 × 104 IU/ml) on at least two occasions have been involved into this clinical trial. Out of 100 HBeAg positive patients, 92 were completed the final Peg-IFNα-2b treatment. Randomized clinical trial were conducted including these 92 naive HBeAg-positive CHB patients. Patients were divided into two groups, one receiving Peg-IFNα-2b alone and one receiving Peg-IFNα-2b in combination with adefovir-dipivoxil in order to simulate patients undergoing treatment with nucleoside analog (NUC).